Insights

Innovative Supplement Launches Valbiotis has recently launched multiple metabolic health dietary supplements, including the Valbiotis PRO Metabolic Health and Valbiotis PRO Cholesterol products. These launches suggest an active effort to expand their product line and capture market share in metabolic disorder solutions, presenting opportunities for partnership or distribution channels.

European Market Expansion With recent developments in France, including the launch of e-commerce platforms and new supplements, there is a clear focus on penetrating and expanding within the European market. Collaborations with local distributors or strategic marketing alliances could accelerate growth in regional markets.

Research-Driven Credibility Valbiotis' receipt of the Young Innovative Company award and substantial EU funding indicates a strong emphasis on R&D and innovation. Partnering for research collaborations or leveraging their scientific credibility could enhance product development and credibility in healthcare or nutraceutical sectors.

Partnership Opportunities Recent strategic partnerships, including collaboration with Minerva Foods, highlight an openness to joint ventures and commercialization initiatives. Exploring similar alliances could expand the reach of Valbiotis’ health products into new distribution channels or geographic markets.

Technology & Digital Presence Valbiotis' deployment of an e-commerce platform and utilization of various web technologies suggests a focus on digital engagement with customers. Digital marketing solutions, online health platforms, or personalized health solutions could be potent areas for business development.

Valbiotis Tech Stack

Valbiotis uses 8 technology products and services including imgix, Cloudimage, WordPress, and more. Explore Valbiotis's tech stack below.

  • imgix
    Content Delivery Network
  • Cloudimage
    Content Delivery Network
  • WordPress
    Content Management System
  • Open Graph
    Content Management System
  • Webpack
    Development
  • Google Tag Manager
    Tag Management
  • Bootstrap
    UI Frameworks
  • X-Content-Type-Options
    Web & Portal Technology

Media & News

Valbiotis's Email Address Formats

Valbiotis uses at least 1 format(s):
Valbiotis Email FormatsExamplePercentage
First.Last@valbiotis.comJohn.Doe@valbiotis.com
50%
First.Last@valbiotis.comJohn.Doe@valbiotis.com
50%

Frequently Asked Questions

Where is Valbiotis's headquarters located?

Minus sign iconPlus sign icon
Valbiotis's main headquarters is located at 12f Rue Paul Vatine Périgny, Nouvelle-aquitaine 17180 France. The company has employees across 1 continents, including Europe.

What is Valbiotis's stock symbol?

Minus sign iconPlus sign icon
Valbiotis is a publicly traded company; the company's stock symbol is ALVAL.PA.

What is Valbiotis's official website and social media links?

Minus sign iconPlus sign icon
Valbiotis's official website is valbiotis.com and has social profiles on LinkedInCrunchbase.

What is Valbiotis's SIC code NAICS code?

Minus sign iconPlus sign icon
Valbiotis's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Valbiotis have currently?

Minus sign iconPlus sign icon
As of February 2026, Valbiotis has approximately 57 employees across 1 continents, including Europe. Key team members include Ceo: S. P.Chief Scientific And Medical Officer: P. S.Quality Assurance Director: C. M.. Explore Valbiotis's employee directory with LeadIQ.

What industry does Valbiotis belong to?

Minus sign iconPlus sign icon
Valbiotis operates in the Biotechnology Research industry.

What technology does Valbiotis use?

Minus sign iconPlus sign icon
Valbiotis's tech stack includes imgixCloudimageWordPressOpen GraphWebpackGoogle Tag ManagerBootstrapX-Content-Type-Options.

What is Valbiotis's email format?

Minus sign iconPlus sign icon
Valbiotis's email format typically follows the pattern of First.Last@valbiotis.com. Find more Valbiotis email formats with LeadIQ.

How much funding has Valbiotis raised to date?

Minus sign iconPlus sign icon
As of February 2026, Valbiotis has raised $9.8M in funding. The last funding round occurred on Nov 08, 2022 for $9.8M.

When was Valbiotis founded?

Minus sign iconPlus sign icon
Valbiotis was founded in 2014.

Valbiotis

Biotechnology ResearchNouvelle-aquitaine, France51-200 Employees

Valbiotis is a commercially oriented Research & Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases in response to unmet medical needs.

Valbiotis has adopted an innovative approach by developing a new class of health nutrition products designed to reduce the risk of major metabolic and cardiovascular diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources.

Created at the beginning of 2014 in La Rochelle, the Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).

Section iconCompany Overview

Headquarters
12f Rue Paul Vatine Périgny, Nouvelle-aquitaine 17180 France
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
ALVAL.PA
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2014
Employees
51-200

Section iconFunding & Financials

  • $9.8M

    Valbiotis has raised a total of $9.8M of funding over 3 rounds. Their latest funding round was raised on Nov 08, 2022 in the amount of $9.8M.

  • $1M

    Valbiotis's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $9.8M

    Valbiotis has raised a total of $9.8M of funding over 3 rounds. Their latest funding round was raised on Nov 08, 2022 in the amount of $9.8M.

  • $1M

    Valbiotis's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.